Biotechnology

Trevena

Trevena Inc. Completes Security Exchange with Institutional Investor

HC Wainwright & Co. Downgrades Trevena (TRVN.US) Rating

Trevena released FY2024 Q3 earnings on November 7, 2024 (EST), with actual revenue of $283,000 and EPS of -5.7915 (forecast EPS was -7.75)

Trevena released FY2024 9 Months Earnings on November 7, 2024 (EST), with actual revenue of 628,000 USD and EPS of -20.5375

Trevena (NASDAQ:TRVN) Rating Changes

Trevena announces $2 million non-dilutive financing

Trevena: Trv045 shows dose-dependent significant increase in seizure threshold measurement results

Trevena Inc: Trv045 did not show statistically significant effects in preliminary clinical models of epilepsy.

Trevena, Inc. Announces Preclinical Data on TRV045, Showing Potential in Chronic Pain and Epilepsy Treatment

Trevena receives letter from NASDAQ Hearings Panel

Trevena Q1 net profit

Trevena released FY2023 Cumulative Q3 Earnings on November 14, 2023 (EST) with Revenue of 3.207 M USD and EPS of -51.8685

Visionary

Sky Quarry

TMD Energy

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Semilux

Cocrystal Pharma

Sidus Space

Swarmer

Franklin Covey

Biodexa Pharmaceuticals

Kiniksa Pharmaceuticals

MiMedx

Rigel Pharma

CapForce Inc.

OpGen

Vertex Pharma

Argenx

Alnylam Pharma

Beigene

Natera

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

Trevena(TRVN.US)

Trevena Stock Performance Chart